Day: September 2, 2024

SAN CARLOS, Calif., Sept. 02, 2024 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, September 3, 2024, at 8:00 a.m. Eastern Time to present topline results from the Phase 1/2 study evaluating the safety, tolerability and immunogenicity of VAX-31, the Company’s 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in healthy adults aged 50 and older. To participate in the conference call, please dial 800-225-9448 (domestic) or 203-518-9708 (international) and refer to conference ID PCVX0903. A live webcast of the conference call will also be available on the investor...

MONTREAL, Sept. 02, 2024 (GLOBE NEWSWIRE) — Velan Inc. (TSX: VLN) (“Velan” or the “Company”), a world-leading manufacturer of industrial valves, announced today that it has entered into a Main Services Agreement (“MSA”) with GEH SMR Technologies Canada Ltd. (“GEH”) to provide certain products and services that may be required by GEH for the provision of a stand-alone Small Modular Reactor (“SMR”) to Ontario Power Generation Inc. Under the terms of the MSA, GEH has placed an initial purchase order with the Company to develop technology and products related thereto. Anticipated future purchase orders for similar SMR’s in Canada, the United States and around the world, the receipt of which are dependent on the Company’s continued ability to develop and deliver required products and services under the MSA, could have a material impact...

BOSTON, Mass., Sept. 02, 2024 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will share the topline results from the Phase 2 EMBOLD study of relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies (DEEs) on Tuesday, September 3, 2024, prior to market open. Following the announcement, the Company will host a conference call and webcast presentation at 8:00 a.m. ET to discuss the trial results. Conference Call and Webcast PresentationDate and Time: Tuesday, September 3, 2024 at 8:00 a.m. ETWebcast: LINK A replay of the presentation will be posted, when...

Nyxoah Rings the Closing Bell at Nasdaq while Preparing for U.S. Market Launch of Innovative Sleep Apnea Device FDA regulatory submission for the Company’s Genio® device is complete, U.S. approval on track for the end of 2024 U.S. commercial launch, expected at the beginning of 2025, fully funded with over €85 million in new capital raisedNyxoah – NASDAQ Closing Bell Ceremony 29 août 2024 Mont-Saint-Guibert, Belgium – September 2, 2024 10:05pm CET / 4:05PM ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), rang the Nasdaq Closing Bell on August 29, 2024 to recognize the Company’s recent progress and highlight upcoming milestones on its path to the U.S. market launch of...

EDF estimates higher nuclear power generation in France for 2024 Thanks to the good industrial performance of France’s nuclear fleet, EDF revises higher its estimate nuclear power generation in France for 2024. Initially estimated between 315-345TWh, nuclear power generation is now estimated between 340-360TWh1. This higher nuclear power generation estimate is based on improved performance of outages and industrial control of stress corrosion inspections and repair work, and the absence of major climatic event during summer. The Group has implemented the START2 2025 action plan aimed at improving the operational efficiency of outages, since 2019. It covers various areas: industrialisation, capitalisation, and standardisation of outages preparation methods, a refined strategy for allocating resources and skills, including the setting...

Magic Square integrates Exodus’ Passkeys Wallet into ‘Magic Store’, offering users seamless crypto management and enhanced security OMAHA, Neb., Sept. 02, 2024 (GLOBE NEWSWIRE) — Magic Square, a pioneering Binance Labs-backed Web3 app store platform, is excited to announce its partnership with Exodus Movement, Inc. (OTCQX: EXOD) (the “Company” or “Exodus”). This collaboration introduces Exodus’s innovative Passkeys Wallet to Magic Square’s ‘Magic Store’ and ‘Magic Launchpad’, enabling users to create and fund a crypto wallet in just a few taps directly within the app, delivering unprecedented ease and industry-leading security. The Passkeys wallet allows users to create a wallet without installing a browser extension and enables them to securely login using options such as FaceID and TouchID. Users can complete KYC to purchase...

A Update on the Flamanville EPR: launch of reactor divergence operations 2 September 2024 – The Nuclear Safety Authority issued EDF with the divergence agreement to proceed with divergence operations on the Flamanville 3 reactor. The power plant’s teams launch the activities required for the first nuclear reaction in the reactor. After loading the reactor last May, Flamanville EPR teams carried out numerous technical tests and put the facilities into the required conditions to initiate nuclear fission.         Divergence will involve creating a stable nuclear reaction at very low power. Once completed, the reactor will be at 0.2% of its rated power. A test programme to achieve a power level of 25% will be implemented. Once at this level, the Flamanville EPR will be connected to the national electricity grid for the first time and...

Ivry-sur-Seine – France, September 2, 2024 Regulated information INFORMATION ON THE TOTAL NUMBER OF SHARES AND VOTING RIGHTS Statement in compliance with article L. 233-8 II of the French commercial code and article 223- 16 of the General Regulation of the French Financial Markets Authority (AMF – Autorité des marchés financiers)Stock Market Euronext Paris  ISIN Code FR0011476928Date   Total number of shares composing the share capital of the company Total number of gross voting rights   Total number of net voting rights (*)August 31, 2024 27,778,578 27,778,578 27,118,042(*) Net = After deduction of the shares deprived of voting right In accordance with Article 9 of the Company’s Articles of Association, any physical or legal person, acting alone or in concert, who comes to hold, or ceases to hold, directly or...